-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
pixabay.
SARS-CoV-2 mRNA 。，。mRNA，。JAMA。
Individuals with immunodeficiency have been excluded from SARS-CoV-2 mRNA vaccine research.Transplant recipients across the United States were recruited through social media to participate in this prospective cohort study, including those who received SARS-CoV-2 vaccination between December 16, 2020 and February 5, 2021.
Transplant recipients across the United States were recruited through social media to participate in this prospective cohort study, including those who received SARS-CoV-2 vaccination between December 16, 2020 and February 5, 2021.
TAPII samples were detected by enzyme immunoassay (EUROIMMUN), and antibodies to the S1 domain of the SARS-CoV-2 spike protein were detected.
The investigators assessed the proportion of patients with a definite binomial 95% CIs that produced a positive antibody response.
A total of 436 transplant recipients were included in the study.
Transplant recipients who receive antimetabolites maintenance immunosuppressive therapy are less likely to develop an antibody response than those who do not receive such immunosuppressive therapy.
In this study on the immunogenicity of the first dose of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients, most subjects did not develop a significant anti-spike antibody response.
In this study on the immunogenicity of the first dose of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients, most subjects did not develop a significant anti-spike antibody response.
These findings indicate that organ transplant recipients have a poorer anti-spike antibody response after receiving the first dose of mRNA vaccine.
References: Boyarsky BJ, Werbel WA, Avery RK, et al.
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.
JAMA.
Published online March 15, 2021.
com/journals/jama/fullarticle/2777685" target="_blank" rel="noopener">doi:10.
1001/jama.
2021.
4385 JAMA.
com/journals/jama/fullarticle/2777685" target="_blank" rel="noopener">doi:10.
1001/jama.
2021.
4385 Leave a message here
